MetaStat, Inc.

MTST

US59140A2033

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:47:00 2023-07-27 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		-.--%	-.--%

2018	MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	CI
2017	MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	CI

MetaStat, Inc. announced that it has received $0.98 million in funding from Dolphin Management Inc.

March 14, 2016

On March 15, 2016, MetaStat, Inc. (OTCPK:MTST) closed the transaction. The company received $625,000 in the final tranche bringing the total funding raised to $975,000.

Latest news about MetaStat, Inc.

MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	18-06-21	CI
MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	17-08-03	CI
MetaStat, Inc. announced that it has received $2.57 million in funding	17-08-02	CI
MetaStat, Inc. announced that it expects to receive $7 million in funding	17-06-22	CI
MetaStat Announces Completion of Second Milestone of its Pilot Research Project with Celgene Corporation	17-06-19	CI
MetaStat, Inc. Appoints Paul Billings to its Board of Directors, Effective as of May 24, 2017	17-05-31	CI
MetaStat, Inc. Announces Management Changes	17-05-08	CI
MetaStat, Inc. Announces Board Changes	17-05-08	CI
MetaStat, Inc. Announces Resignation of Martin J. Driscoll from the Board of Directors	17-04-28	CI
MetaStat, Inc. Presents Supportive Data for the Role of Mena Protein Isoforms in Tumor Dissemination at the 2017 American Association of Cancer Research Annual Meeting	17-04-06	CI
MetaStat, Inc. Receives Additional State Clinical Laboratory Licenses	16-12-19	CI
MetaStat, Inc. Presents Positive Data from Two Clinical Studies of Metasite Breast at 2016 San Antonio Breast Cancer Symposium	16-12-13	CI
MetaStat, Inc. announced that it has received $2.61 million in funding	16-10-20	CI
MetaStat, Inc. cancelled the transaction announced on October 10, 2014	16-10-09	CI
MetaStat, Inc. and Celgene Corporation Enter into Amendment to Pilot Materials Transfer Agreement	16-10-06	CI
MetaStat, Inc. Announces Resignation of Johan M. Spoor as Board of Directors	16-09-07	CI
MetaStat, Inc. announced that it expects to receive $20 million in funding	16-08-30	CI
MetaStat, Inc. announced that it has received $0.5 million in funding	16-06-07	CI
MetaStat, Inc. announced that it expects to receive $5 million in funding	16-05-25	CI
MetaStat, Inc. Names Jerome B. Zeldis as Vice Chairman of the Board of Directors	16-04-27	CI
Metastat, Inc. Appoints Anthony Shuber as Head of Diagnostic Research and Development	16-03-24	CI
MetaStat, Inc. announced that it has received $0.98 million in funding from Dolphin Management Inc.	16-03-14	CI
MetaStat, Inc. Announces Resignation of Mark Gustavson as Vice President of Diagnostics	16-03-11	CI
MetaStat, Inc. announced that it expects to receive $1 million in funding from Dolphin Management Inc, and other investors.	16-02-11	CI
MetaStat Announces Completion of Analytical Validation Study of its MenaCalc Cancer Diagnostic Platform	16-01-26	CI

MetaStat, Inc. is a precision medicine company. The Company's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The Company's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
METASTAT, INC.	-.--%	587
MODERNA, INC.	+49.21%	56.95B
LONZA GROUP AG	+39.98%	40.26B
IQVIA HOLDINGS INC.	-6.86%	39.32B
CELLTRION, INC.	-4.42%	28.37B
ICON PUBLIC LIMITED COMPANY	+12.00%	26.45B
ALNYLAM PHARMACEUTICALS, INC.	-18.27%	19.41B
MEDPACE HOLDINGS, INC.	+29.57%	12.54B
UNITED THERAPEUTICS CORPORATION	+25.41%	12.21B
BIO-TECHNE CORPORATION	-0.35%	12.15B

Other Biotechnology & Medical Research

MetaStat, Inc.

Equities

MTST

US59140A2033

Biotechnology & Medical Research

MetaStat, Inc. announced that it has received $0.98 million in funding from Dolphin Management Inc.

Latest news about MetaStat, Inc.

Chart MetaStat, Inc.

Company Profile

Sector Other Biotechnology & Medical Research